Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ: XERS )

4.880 +0.320 (+7.02%)
Streaming Delayed Price Updated: 3:43 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Xeris Biopharma - Possibly The Best Pharma Stock
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. 
Via Talk Markets
Topics Stocks / Equities
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
Via Stocktwits
These stocks are gapping in today's session
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Why Xeris Biopharma Shares Are Trading Higher Today
Xeris Biopharma Holdings Inc (NASDAQ: XERS) shares are trading higher by around 9% after the 
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Xeris Pharmaceuticals's Earnings Outlook
Via Benzinga
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024
XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Are Xeris Biopharma Shares Moving Monday?
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and... 
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down
Chewy stock is falling on Wednesday after it was announced that Morgan Stanley is handling a block sale of CHWY shares. 
Via InvestorPlace
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
Via Benzinga
Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement. 
Via InvestorPlace
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market. 
Via InvestorPlace
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
$8M Bet On Vicarious Surgical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.